About
Us
Our mission is to accelerate the discovery of safe and effective therapeutic strategies targeting rare and difficult to treat cancers.
BioXplor was established in 2017 and consists of an experienced, multidisciplinary team of experts in computational sciences, biomedical sciences, drug discovery and clinical development. The company is backed by leading startup accelerators including SkyDeck (UC Berkeley), Merck, Creative Destruction Labs (University of Oxford), European Institute of Technology and Innovation (EIT Health) and European Innovation Council (EIC / Horizon 2020). BioXplor's investors include UC Berkeley's SkyDeck Fund, Enterprise Ireland and IronFire Ventures. Our clients and partners include top tier pharmaceutical companies like Novartis, Amgen, Bayer and Merck.
MANAGEMENT TEAM & ADVISORY BOARD
Mark Rogers, MSc
Co-Founder & CEO
Co-Founder & COO
Co-Founder & CTO
Anna O'Leary, BA
Pavel Kartasev, MEng, MSc
Head of Machine Learning
John Conway, MSc
Advisor
Advisor
Advisor
David Kwon, MD, PhD, MBA
Prof. Jody J. Haigh, PhD
Bill Allison
Clinical Development Director
Pharmacology and Therapeutics
CTO at UC Berkeley
